Updated on 2025/04/18

写真a

 
Hashimoto Masashi
 
Organization
Scheduled update Special-Appointment Assistant Professor
Position
Special-Appointment Assistant Professor
External link

Degree

  • Ph.D ( 2024.9   Okayama University, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences )

  • M.D ( 2011.3   Okayama University Medical School Faculty of Medicine )

Research Areas

  • Life Science / Tumor diagnostics and therapeutics

 

Papers

  • Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis. Reviewed

    Noriyuki Nishiwaki, Kazuhiro Noma, Tomoyoshi Kunitomo, Masashi Hashimoto, Naoaki Maeda, Shunsuke Tanabe, Kazufumi Sakurama, Yasuhiro Shirakawa, Toshiyoshi Fujiwara

    Esophagus : official journal of the Japan Esophageal Society   19 ( 4 )   626 - 638   2022.10

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: The standard treatment for locally advanced esophageal cancer is preoperative chemotherapy with cisplatin and 5-fluorouracil (CF), followed by surgery. Although docetaxel plus cisplatin and 5-fluorouracil (DCF) has been reported to have favorable outcomes, no study has compared its therapeutic efficacy to that of standard treatment. This study aimed to compare the therapeutic effects of CF and DCF in the real world by matching patient background factors using propensity scores. METHODS: We retrospectively reviewed the data of 237 patients with esophageal squamous cell carcinoma who underwent esophagectomy between January 2008 and December 2018. Patients were divided into two groups based on the preoperative chemotherapy regimens of CF (79 patients) or DCF (158 patients), and 49 matched pairs were finally analyzed using propensity score matching. Short- and long-term outcomes were compared between groups. RESULTS: After matching, although no significant differences in survival were observed among the groups, patients receiving DCF showed a significantly high histological response (P < 0.001). Subgroup analyses demonstrated that DCF therapy had better overall survival (P = 0.046) and relapse-free survival (P = 0.010) among pathological T3 and T4 cases. Whereas, adverse effects of chemotherapy were more frequent in the DCF group. CONCLUSIONS: Patients receiving DCF had higher pathological response and better survival than those receiving CF, especially in pathological T3 and T4 cases matched using propensity scores. Thus, the DCF regimen might be an effective treatment for locally advanced esophageal cancer. However, the adverse side effects of chemotherapy remain high and should be handled appropriately.

    DOI: 10.1007/s10388-022-00934-5

    PubMed

    researchmap

  • Initial introduction of robot-assisted, minimally invasive esophagectomy using the microanatomy-based concept in the upper mediastinum. Reviewed International journal

    Yasuhiro Shirakawa, Kazuhiro Noma, Tomoyoshi Kunitomo, Masashi Hashimoto, Naoaki Maeda, Shunsuke Tanabe, Kazufumi Sakurama, Toshiyoshi Fujiwara

    Surgical endoscopy   35 ( 12 )   6568 - 6576   2021.12

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: We have recently standardized upper mediastinal lymph node dissection (UMLND) using a microanatomy-based concept in thoracoscopic esophagectomy in the prone position (TEPP), and introduced robot-assisted minimally invasive esophagectomy (RAMIE) using the same concept as in TEPP while aiming at solo surgery. The purpose of this study was to investigate the outcomes of RAMIE using the microanatomy-based concept in the initial introduction phase. METHODS: We have performed more than 500 TEPP procedures as minimally invasive esophagectomy (MIE). After performing about 400 cases of MIE, we established a microanatomy-based standardization of UMLND. In October 2018, we introduced RAMIE, and have performed 75 procedures in 20 months. Two groups were analyzed: a group after microanatomy-based standardization in TEPP (100 cases after completing 400 cases of TEPP) and a RAMIE group (75 cases). Finally, 51 paired cases were matched using a propensity score. Furthermore, the change in postoperative short-term outcome for RAMIE in the initial introduction phase was analyzed. RESULTS: Although there were no significant differences between the two groups in the number of upper mediastinal lymph nodes dissected, there was a significant decrease (P = 0.036) in intraoperative blood loss volume with RAMIE, representing a definite benefit for patients. The thoracoscopic operative time for RAMIE decreased by almost 100 min following less than 50 cases of experience, reaching the same level as that for recent TEPP, but with only one-tenth the operator experience. There were no significant differences in the total postoperative morbidity rate including the recurrent laryngeal nerve palsy rate. CONCLUSION: RAMIE has been introduced safely and smoothly using the microanatomy-based concept established in TEPP.

    DOI: 10.1007/s00464-020-08154-7

    PubMed

    researchmap

  • Immune Modulation by Telomerase-Specific Oncolytic Adenovirus Synergistically Enhances Antitumor Efficacy with Anti-PD1 Antibody. Reviewed International journal

    Nobuhiko Kanaya, Shinji Kuroda, Yoshihiko Kakiuchi, Kento Kumon, Tomoko Tsumura, Masashi Hashimoto, Toshiaki Morihiro, Tetsushi Kubota, Katsuyuki Aoyama, Satoru Kikuchi, Masahiko Nishizaki, Shunsuke Kagawa, Hiroshi Tazawa, Hiroyuki Mizuguchi, Yasuo Urata, Toshiyoshi Fujiwara

    Molecular therapy : the journal of the American Society of Gene Therapy   28 ( 3 )   794 - 804   2020.3

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    The clinical benefit of monotherapy involving immune checkpoint inhibitors (ICIs) such as anti-programmed death-1 antibody (PD-1 Ab) is limited to small populations. We previously developed a telomerase-specific oncolytic adenovirus, Telomelysin (OBP-301), the safety of which was confirmed in a phase I clinical study. Here, we examined the potential of OBP-502, an OBP-301 variant, as an agent for inducing immunogenic cell death (ICD) and synergistically enhancing the efficacy of OBP-502 with PD-1 Ab using CT26 murine colon cancer and PAN02 murine pancreatic cancer cell lines. OBP-502 induced the release of ICD molecules such as adenosine triphosphate (ATP) and high-mobility group box protein 1 (HMGB1) from CT26 and PAN02 cells, leading to recruitment of CD8-positive lymphocytes and inhibition of Foxp3-positive lymphocyte infiltration into tumors. Combination therapy involving OBP-502 intratumoral administration and PD-1 Ab systemic administration significantly suppressed the growth of not only OBP-502-treated tumors but also tumors not treated with OBP-502 (so-called abscopal effect) in CT26 and PAN02 bilateral subcutaneous tumor models, in which active recruitment of CD8-positve lymphocytes was observed even in tumors not treated with OBP-502. This combined efficacy was similar to that observed in a CT26 rectal orthotopic tumor model involving liver metastases. In conclusion, telomerase-specific oncolytic adenoviruses are promising candidates for combined therapies with ICIs.

    DOI: 10.1016/j.ymthe.2020.01.003

    PubMed

    researchmap

  • Induction chemoradiotherapy including docetaxel, cisplatin, and 5-fluorouracil for locally advanced esophageal cancer. Reviewed

    Hashimoto M, Shirakawa Y, Maeda N, Tanabe S, Noma K, Sakurama K, Katsui K, Nishizaki M, Fujiwara T

    Esophagus : official journal of the Japan Esophageal Society   17 ( 2 )   127 - 134   2020.1

     More details

    Language:English   Publishing type:Research paper (scientific journal)  

    BACKGROUND: Locally advanced esophageal cancer (EC) invading surrounding organs (T4b) is difficult to treat. In general, definitive chemoradiotherapy (d-CRT) has been chosen as treatment for such cases. However, the outcome has not been good. Recently, the effectiveness of d-CRT with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) has been reported. Furthermore, surgery after d-CRT has a better prognosis than d-CRT alone in some reports, although it has a high risk of surgical complications. This study investigated the effectiveness and safety of induction DCF-RT. METHODS: The subjects were EC patients who underwent induction DCF-RT in Okayama University Hospital between January 2011 and December 2017. Their background characteristics, treatment details, histopathological factors, adverse events during CRT, postoperative complications, and overall survival (OS) were assessed. RESULTS: A total of 16 cases were performed induction DCF-RT. In 10 cases, death occurred, with 9 cancer-related deaths, and 1 death due to other disease. For all cases, OS was 37.5% at 3 years. 12 cases underwent esophagectomy after DCF-RT. Their OS was 50% at 3 years. 13 patients (81.3%) had Grade 3 febrile neutropenia. In 7 cases (62.5%), fasting for the treatment of diarrhea was needed. Three patients (25%) developed anastomotic leakage. Some recurrent laryngeal nerve paralysis was observed in 6 cases (50%). CONCLUSION: Although the rates of adverse events and surgical complications were slightly higher than in past reports, they were acceptable. It is useful to perform induction DCF-RT for T4b EC.

    DOI: 10.1007/s10388-019-00709-5

    PubMed

    researchmap

  • Prognosis and prognostic factors of esophageal spindle cell carcinoma treated by esophagectomy: a retrospective single-institution analysis Reviewed

    Masashi Hashimoto, Hidehiko Kitagami, Hiroki Niwa, Tomohiro Kikkawa, Tomoyuki Ohuchi, Toshinao Takenouchi, Masao Hosokawa

    Esophagus   16 ( 3 )   292 - 299   2019.7

     More details

    Publishing type:Research paper (scientific journal)   Publisher:Springer Science and Business Media {LLC}  

    DOI: 10.1007/s10388-019-00667-y

    researchmap

▼display all

MISC

  • 難治性胃食道逆流症・食道裂孔ヘルニアに対する腹腔鏡手術によるQOL改善効果

    田辺俊介, 野間和広, 河崎健人, 國友知義, 橋本将志, 賀島肇, 前田直見, 菊地覚次, 白川靖博, 藤原俊義

    日本食道学会学術集会抄録集(CD-ROM)   78th   2024

  • 膵頭十二指腸切除術周術期ERASプロトコールにおけるロボット支援下手術の意義

    高木弘誠, 菊地覚次, 橋本将志, 前田直見, 田辺俊介

    日本臨床栄養代謝学会学術集会(Web)   39th   2024

  • 超低肺機能の食道癌患者に対する術式と周術期管理の工夫

    松本眞琴, 野間和広, 河崎健人, 國友知義, 橋本将志, 賀島肇, 前田直見, 田邊俊介, 白川靖博, 藤原俊義

    日本食道学会学術集会抄録集(CD-ROM)   78th   2024

  • DCFとロボット支援下手術を駆使して挑むcT3br,cT4食道癌症例に対する挑戦

    野間和広, 河崎健人, 國友知義, 橋本将志, 賀島肇, 前田直見, 菊地覚次, 田辺俊介, 白川靖博, 藤原俊義

    日本食道学会学術集会抄録集(CD-ROM)   78th   2024

  • 当院における高齢者食道癌の術後合併症の検討

    高橋政史, 野間和広, 河崎健人, 國友知義, 橋本将志, 前田直見, 菊池覚次, 田辺俊介, 白川靖博, 白川靖博, 藤原俊義

    日本食道学会学術集会抄録集(CD-ROM)   78th   2024

▼display all

Presentations

  • 食道癌術後補助免疫療法中の早期再発リスクと免疫関連有害事象の検討

    橋本 将志, 野間 和広, 加藤 卓也, 前田 直見, 田辺 俊介, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本消化器外科学会総会  2023.7  (一社)日本消化器外科学会

     More details

    Event date: 2023.7

    Language:Japanese  

    researchmap

  • cStage II/IIIA食道癌:DCF NAC後の術後補助療法とその適応 pN2以上の再発リスクに対する術後補助免疫療法の短期成績

    橋本 将志, 野間 和広, 河崎 健人, 國友 知義, 賀島 肇, 加藤 卓也, 前田 直見, 菊地 覚次, 田辺 俊介, 白川 靖博, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集  2023.6  (NPO)日本食道学会

     More details

    Event date: 2023.6

    Language:Japanese  

    researchmap

  • 術前DCF療法を行った食道癌切除後の再発パターンと再発リスク因子

    橋本 将志, 野間 和広, 前田 直見, 菊地 覚次, 重安 邦俊, 田辺 俊介, 近藤 喜太, 黒田 新士, 吉田 龍一, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本臨床外科学会雑誌  2022.10  日本臨床外科学会

     More details

    Event date: 2022.10

    Language:Japanese  

    researchmap

  • 食道癌に対するウイルス治療、ワクチン治療の最前線 抗腫瘍免疫賦活を介した腫瘍融解アデノウイルス製剤による免疫チェックポイント阻害薬治療増強効果の検討

    橋本 将志, 黒田 新士, 金谷 信彦, 田辺 俊介, 前田 直見, 野間 和広, 田澤 大, 白川 靖博, 浦田 泰生, 藤原 俊義

    日本食道学会学術集会プログラム・抄録集  2022.9  (NPO)日本食道学会

     More details

    Event date: 2022.9

    Language:Japanese  

    researchmap

  • ロボット支援手術による左上縦隔郭清の定型化

    前田 直見, 野間 和広, 河崎 健人, 國友 知義, 橋本 将志, 加藤 卓也, 重安 邦俊, 菊地 覚次, 黒田 新士, 近藤 喜太, 田辺 俊介, 寺石 文則, 楳田 祐三, 白川 靖博, 藤原 俊義

    日本内視鏡外科学会雑誌  2023.12  (一社)日本内視鏡外科学会

     More details

    Event date: 2023.12

    Language:Japanese  

    researchmap

▼display all

Awards

  • 第43回癌免疫外科研究会奨励賞

    2022.5   癌免疫外科研究会   p53搭載腫瘍融解アデノウイルス製剤の膵癌マウスモデルにおける長期抗腫瘍免疫増強効果

     More details

  • 藤田記念医学研究振興基金研究助成

    2022   日本学術振興会   長期抗腫瘍免疫を介した術前ウイルス療法と術後補助免疫療法の異時的併用効果の検討

     More details

Research Projects

  • Validation of Tumor Immune Remodeling Effects of CAF Targeted Therapy in ICI Resistance

    Grant number:24K02520  2024.04 - 2028.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research  Grant-in-Aid for Scientific Research (B)

    野間 和広, 橋本 将志, 大原 利章, 菊地 覚次, 賀島 肇, 冨樫 庸介

      More details

    Grant amount:\18460000 ( Direct expense: \14200000 、 Indirect expense:\4260000 )

    researchmap

  • 術前ウイルス療法による長期抗腫瘍免疫賦活を介した術後免疫療法効果増強の検討

    Grant number:23K08213  2023.04 - 2026.03

    日本学術振興会  科学研究費助成事業 基盤研究(C)  基盤研究(C)

    橋本 将志

      More details

    Grant amount:\4810000 ( Direct expense: \3700000 、 Indirect expense:\1110000 )

    researchmap

  • the superiority of the p53 overexpressing oncolytic adenovirus mediated tumor-specific to chemotherapies in immunotherapy for a pancreatic cancer

    Grant number:20K17690  2020.04 - 2022.03

    Japan Society for the Promotion of Science  Grants-in-Aid for Scientific Research Grant-in-Aid for Early-Career Scientists  Grant-in-Aid for Early-Career Scientists

    Hashimoto Masashi

      More details

    Grant amount:\4160000 ( Direct expense: \3200000 、 Indirect expense:\960000 )

    Pancreatic cancer is aggressive cancer with an immunologically “cold” microenvironment. We developed a telomerase-specific oncolytic adenovirus armed with p53 gene (OBP-702). Here, we investigated the immunological efficacy of OBP-702 for pancreatic cancer. Activation of CD8+ T cells by OBP-702 was retained in combination with gemcitabine+nab-paclitaxel (GN) in a PAN02 bilateral tumor model, and GN+OBP-702 showed significant anti-tumor effects and increased CD8+ T cells in OBP-702-un-injected tumors. Finally, GN+OBP-702 sustained long-term anti-tumor effects in a neoadjuvant model even after tumor resection. In conclusion, OBP-702 can be a long-term immunostimulant which brings sustained anti-tumor effects on immunologically cold pancreatic cancer.

    researchmap